Quantum Genomics (France) Performance
| ALQGC Stock | EUR 0.07 0 1.77% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Quantum Genomics are completely uncorrelated. Quantum Genomics right now holds a risk of 0.0%. Please check Quantum Genomics accumulation distribution and market facilitation index , to decide if Quantum Genomics will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Quantum Genomics SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Quantum Genomics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 27.2 M | |
| Total Cashflows From Investing Activities | -45 K |
Quantum |
Quantum Genomics Relative Risk vs. Return Landscape
If you would invest 7.21 in Quantum Genomics SA on November 4, 2024 and sell it today you would earn a total of 0.00 from holding Quantum Genomics SA or generate 0.0% return on investment over 90 days. Quantum Genomics SA is generating negative expected returns and assumes 0.0% volatility on return distribution over the 90 days horizon. Simply put, 0% of stocks are less volatile than Quantum, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Quantum Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Quantum Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Quantum Genomics SA, and traders can use it to determine the average amount a Quantum Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ALQGC |
Based on monthly moving average Quantum Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Quantum Genomics by adding Quantum Genomics to a well-diversified portfolio.
Quantum Genomics Fundamentals Growth
Quantum Stock prices reflect investors' perceptions of the future prospects and financial health of Quantum Genomics, and Quantum Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Quantum Stock performance.
| Return On Equity | -1.23 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (5.48) % | |||
| Current Valuation | (11.33 M) | |||
| Shares Outstanding | 34.53 M | |||
| Price To Earning | (5.10) X | |||
| Price To Book | 0.32 X | |||
| Price To Sales | 1.07 X | |||
| Revenue | 116.21 K | |||
| EBITDA | (18.94 M) | |||
| Cash And Equivalents | 5.01 M | |||
| Cash Per Share | 0.89 X | |||
| Total Debt | 283.69 K | |||
| Book Value Per Share | 0.44 X | |||
| Cash Flow From Operations | (17.02 M) | |||
| Earnings Per Share | (0.73) X | |||
| Total Asset | 22.59 M | |||
About Quantum Genomics Performance
Assessing Quantum Genomics' fundamental ratios provides investors with valuable insights into Quantum Genomics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Quantum Genomics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people.Things to note about Quantum Genomics performance evaluation
Checking the ongoing alerts about Quantum Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Quantum Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Quantum Genomics generated a negative expected return over the last 90 days | |
| Quantum Genomics has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 116.21 K. Net Loss for the year was (17.36 M) with loss before overhead, payroll, taxes, and interest of (12.47 M). | |
| Quantum Genomics SA has accumulated about 5.01 M in cash with (17.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Quantum Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Quantum Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Quantum Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Quantum Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Quantum Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Quantum Genomics' stock. These opinions can provide insight into Quantum Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.